Dyne Therapeutics (DYN) Operating Expenses (2019 - 2026)
Dyne Therapeutics (DYN) posted quarterly Operating Expenses of $181.7 million for Q2 2026, up 56.89% year-over-year from $115.8 million in Q2 2025, and up 45.01% quarter-over-quarter from $125.3 million in Q1 2026.
Dyne Therapeutics (DYN) Operating Expenses (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Operating Expenses for 8 consecutive years, with $181.7 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Operating Expenses rose 56.89% year-over-year to $181.7 million; the TTM figure through Jun 2026 stood at $537.0 million (up 21.78% YoY), while the FY2025 annual figure was $468.2 million, up 36.15% from the prior year.
- Operating Expenses grew to $181.7 million in Q2 2026 per DYN's latest filing, from $125.3 million in the prior quarter.
- Across five years, Operating Expenses topped out at $181.7 million in Q2 2026 and bottomed at $35.8 million in Q1 2022.
- Historically, Operating Expenses has averaged $85.1 million across 5 years, with a median of $70.6 million in 2024.
- Annual changes were most pronounced in 2022 — Operating Expenses retreated 22.74% — and 2025, when it soared 76.95%.
- Dyne Therapeutics' Operating Expenses stood at $40.1 million in 2022, then jumped by 68.61% to $67.7 million in 2023, then jumped by 43.46% to $97.1 million in 2024, then gained by 19.59% to $116.1 million in 2025, then jumped by 56.43% to $181.7 million in 2026.
- Business Quant data shows DYN's Operating Expenses at $181.7 million in Q2 2026, $125.3 million in Q1 2026, and $116.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Dyne Therapeutics | 4.26 Bn | 4.26 Bn | - | 181.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 181.66 Mn |
| Mar 31, 2026 | 125.28 Mn |
| Dec 31, 2025 | 116.13 Mn |
| Sep 30, 2025 | 113.89 Mn |
| Jun 30, 2025 | 115.79 Mn |
| Mar 31, 2025 | 122.37 Mn |
| Dec 31, 2024 | 97.11 Mn |
| Sep 30, 2024 | 105.66 Mn |
| Jun 30, 2024 | 71.96 Mn |
| Mar 31, 2024 | 69.16 Mn |
| Dec 31, 2023 | 67.69 Mn |
| Sep 30, 2023 | 62.27 Mn |
| Jun 30, 2023 | 66.74 Mn |
| Mar 31, 2023 | 45.46 Mn |
| Dec 31, 2022 | 40.15 Mn |
| Sep 30, 2022 | 42.28 Mn |
| Jun 30, 2022 | 52.76 Mn |
| Mar 31, 2022 | 35.78 Mn |
| Dec 31, 2021 | 51.96 Mn |
| Sep 30, 2021 | 42.77 Mn |